All In Biotech

NDA 206829 · Cubist Pharms LLC

Zerbaxa

Ceftolozane Sulfate, Tazobactam Sodium · Intravenous

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Dec 19, 2014

Approved uses

5

Original approval plus efficacy supplements

Registered trials

26

7 Phase 3, 2 recruiting

FAERS reports

982

670 serious, 233 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2026.

ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms in adult and pediatric patients (at least 32 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole. ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis. ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP). ( 1.3 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) 1.1 Complicated Intra-abdominal Infections ZERBAXA used in combination with metronidazole is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius . 1.2 Complicated Urinary Tract Infections, Including Pyelonephritis ZERBAXA is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli ,...

Mechanism: ZERBAXA is an antibacterial drug [see Clinical Pharmacology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 12, 2026 Supplement 23 · Efficacy · priority review LetterLabel
  • Apr 21, 2022 Supplement 11 · Efficacy LetterLabel
  • Apr 21, 2022 Supplement 12 · Efficacy LetterLabel
  • Jun 3, 2019 Supplement 8 · Efficacy · priority review LetterLabelReview
  • Dec 19, 2014 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelSummary ReviewLetter
1 products under this application
  • ZERBAXA · CEFTOLOZANE SULFATE EQ 1GM BASE/VIAL; TAZOBACTAM SODIUM EQ 0.5GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ceftolozane" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use139
  • product use in unapproved indication128
  • no adverse event90
  • death81
  • product use issue67
  • pathogen resistance54
  • drug ineffective44
  • acute kidney injury36
  • drug resistance30
  • encephalopathy27
  • incorrect dose administered26
  • pancytopenia26

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201545
201685
2017126
2018135
2019126
2020145
202142
202255
202382
202467
202549
202625

Recalls

1 FDA enforcement reports for this application.

  • Dec 21, 2020 · Class II · Terminated

    Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zerbaxa (Ceftolozane/Tazobactam)

2024 spending

$18.0M

Beneficiaries

1,128

5,087 claims

Per beneficiary

$15,974

$24.65 per unit

View as table
YearSpending
2020$8,252,292
2021$52,147
2022$7,206,260
2023$12,776,957
2024$18,018,166

Part B: Zerbaxa (Ceftolozane/Tazobactam) · HCPCS J0695

2024 spending

$280K

Beneficiaries

126

499 claims

Per beneficiary

$2,222

2024 ASP limit $7.78 per unit

View as table
YearSpending
2020$693,355
2021$8,380
2022$401,270
2023$213,774
2024$279,922

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 75 on PubMed

Sponsor: Cubist Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.